Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies

Area of Science:

• Cardiovascular toxicology
• Pharmacology
• Cellular stress response

Background:

• Imatinib mesylate is a tyrosine kinase inhibitor used in cancer therapy.
• Potential cardiotoxicity of imatinib at high concentrations requires investigation.

Purpose of the Study:

• To evaluate the cardiotoxicity of imatinib mesylate in preclinical models.
• To determine if imatinib induces apoptosis or endoplasmic reticulum stress in cardiac cells.

Main Methods:

• Neonatal rat ventricular myocytes and fibroblasts were treated with imatinib.
• In vivo studies in mice and rats using oral and intraperitoneal imatinib administration.
• Assessment of apoptosis, endoplasmic reticulum stress, cardiovascular pathology, and cardiac hypertrophy.

Main Results:

• Cytotoxic imatinib concentrations (10-50 microM) induced apoptosis and ER stress markers in isolated cardiac cells.
• No significant cardiovascular pathology or heart failure was observed in mice treated with imatinib.
• High oral doses of imatinib in rats led to cardiac hypertrophy, potentially linked to multi-organ toxicities.

Conclusions:

• Imatinib mesylate is not cardiotoxic at clinically relevant concentrations (5 microM).
• Observed cardiac hypertrophy in rats at high doses may be an indirect effect of systemic toxicity.
• Further research should consider the impact of systemic effects on cardiac health.